cyclopentane has been researched along with belinostat in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Berger, AJ; Chalasani, S; Chen, S; Dai, Y; Dumur, CI; Ferreira-Gonzalez, A; Grant, S; Kmieciak, M; Leng, Y; Li, L; Lin, H; Povirk, L; Rahmani, M; Rizzo, KA; Zhang, Y; Zhou, L | 1 |
1 other study(ies) available for cyclopentane and belinostat
Article | Year |
---|---|
The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Topics: Animals; Apoptosis; Bcl-2-Like Protein 11; Cell Cycle Proteins; Cells, Cultured; Checkpoint Kinase 1; Cyclopentanes; DNA Damage; DNA Repair; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Mice; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neoplasm Proteins; NF-kappa B; Nuclear Proteins; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Pyrimidines; RNA Interference; RNA, Small Interfering; S Phase Cell Cycle Checkpoints; Sulfonamides; U937 Cells; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays | 2016 |